Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
VeerHealth Care will be raising Rs. 8 crores through bank borrowings
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The 200 bedded hospital owned & operated by Alexis
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Subscribe To Our Newsletter & Stay Updated
